Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 16/20 | 0.49 |
| ▸ | BCL9 | O00512 | 15/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16713005 | 0.92 | PLAU (0.56) | CTNNB1BCL9PLGPLAUPLAT | |
| SCHEMBL23969925 | 0.92 | CTNNB1 (0.48) | CTNNB1BCL9PLGPLAUPLAT | |
| SCHEMBL23970020 | 0.92 | HSP90AA1 (0.49) | CTNNB1BCL9PLGPLAUPLAT | |
| SCHEMBL23970007 | 0.91 | CTNNB1 (0.51) | CTNNB1BCL9PLGPLAUPLAT | |
| SCHEMBL23969919 | 0.89 | PLG (0.46) | CTNNB1BCL9PLGPLAUPLAT | |
| SCHEMBL23970069 | 0.89 | CTNNB1 (0.50) | CTNNB1BCL9PLAUPLAT | |
| SCHEMBL23969970 | 0.87 | PLAU (0.56) | CTNNB1BCL9PLGPLAUPLAT | |
| SCHEMBL22529542 | 0.87 | MCHR1 (0.49) | CTNNB1BCL9PLGPLAUPLAT | |
| SCHEMBL29460661 | 0.87 | MCHR1 (0.49) | CTNNB1BCL9PLGPLAUPLAT | |
| SCHEMBL23969926 | 0.86 | IDO1 (0.49) | CTNNB1BCL9PLGPLAUPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168427-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168427-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, RPS27A, HSPBP1 | CTNNB1 2700/4885BCL9 1021/4885PLG 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.